Ipsat Therapies Oy Company Profile

20:09 EST 16th February 2020 | BioPortfolio

Ipsat Therapies Ltd is a Finnish biotechnology company developing its proprietary IPSAT™ (“Intestinal Protection System in Antibiotic Treatment”) family of products for the prevention of hospital infections and antibiotic resistance


Helsinki Business and Science Park
Viikinkaari 4


Phone: 358 9 3193 6500
Fax: 358 9 3193 6519

News Articles [232 Associated News Articles listed on BioPortfolio]

TScan Closes on Series B to Develop Next-Generation Immuno-Oncology Therapies

The company’s focus is on improving immuno-oncology therapies, making them more effective for the patients for whom these new therapies don’t work and by decreasing serious side effects.

Advanced Therapies Feature in New IMI Call for Proposals

Advanced therapies are a major part of new Innovative Medicines Initiative (IMI) Calls for proposals. The two advanced therapies topics aim to accelerate research into advanced therapies for rare dise...

Complementary and alternative therapies to treat colic

(University of Bristol) A review of the evidence on the use of complementary and alternative (CAM) therapies to treat babies with colic has shown some that some treatments -- including probiotics, fen...

ACPs to lead gene therapies in haemophilia market growth

New therapies to hit existing players

NIH, Gates pledge $200m for HIV and sickle cell gene therapies

Aim to bring therapies to patients in lower-income countries

BioRestorative Therapies Featured in IEEE Pulse Magazine’s Cover Story About Stem Cell Therapies for Low Back Pain

MELVILLE, N.Y., Dec. 16, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based th...

Novel imPACT Isolation Technology Opens Doors to Improved Personalized Therapies

Researchers are working to improve methods to identify new targets for these therapies in hopes to develop more effective and personalized therapies. The method allows researchers to identify the T ce...

Technologies for the directed evolution of cell therapies

New research highlights how the next generation of therapies are moving beyond the use of small molecules and proteins to using whole cells.

Drugs and Medications [1 Associated Drugs and Medications listed on BioPortfolio]

Byetta [astrazeneca pharmaceuticals lp]

These highlights do not include all the information needed to use BYETTA safely and effectively. See full prescribing information for BYETTA. BYETTA® (exenatide) injection, for subcutaneous useInitia...

PubMed Articles [544 Associated PubMed Articles listed on BioPortfolio]

The use of biologic therapies for the management of pediatric asthma.

With better understanding of the role of type 2 inflammation in allergic asthma, there has been progress made in the development of new biologic therapies targeting these specific pathways. This revie...

Effect of acupoint therapies on prostatitis: A systematic review protocol.

Prostatitis is a common urinary infectious disease. Acupoint therapies, including massage, acupuncture, acupoints injection, acupressure, and moxibustion, showed clinical and long-lasting benefits for...

Novel therapies in myelodysplastic syndromes.

Currently, there is a rapid expansion of novel, efficacious therapies for the treatment of patients with myelodysplastic syndromes (MDS) at a rate never seen to date. In this review, we will outline n...

Non-antibiotic therapy for infection: A review.

infection (CDI) is a common infectious disease that is mainly caused by antibiotics. Antibiotic therapy is still the dominant treatment for CDI, although it is accompanied by side effects. Probiotics,...

A Hospital-based Study of the Prevalence and Usage of Complementary and Alternative Medicine Among Saudi Psychiatric Patients.

Introduction Complementary and alternative medicine (CAM) therapies, used singularly or in combination with more conventional therapies, are routinely used by citizens of the Kingdom of Saudi Arabia (...

Clinical Trials [1984 Associated Clinical Trials listed on BioPortfolio]

A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

The purpose of this study is to observe and describe treatment patterns, like Overactive Bladder (OAB) treatment discontinuation, switching to other therapies and persistence of OAB therap...

Effect of Complementary and Alternative Medicine on Pain Among Inpatients

The proposed study has 3 aims: 1) quantitatively describe a model for delivering complementary and alternative medicine (CAM) therapies to understand the selection of patients and CAM ther...

Single Patient Treatment of Posaconazole in Invasive Fungal Infections (Study P05113)(COMPLETED)

The purpose of this study is to provide posaconazole compassionate treatment to patients with invasive fungal infections: 1) which are resistant to standard antifungal therapies; 2) for wh...

Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies

This is a 2‑arm, randomized, placebo-controlled, double‑blind, international, multicenter study comparing the efficacy of DCC-2618 to placebo in patients who have received treatment wi...

Intensive Therapies in Children With Hemiplegia

This is a comparative study where two protocols of intensive therapies will be applied to study the improvements in the functional performance of the affected upper limb of children with h...

Companies [967 Associated Companies listed on BioPortfolio]

Ipsat Therapies Oy

Ipsat Therapies Ltd is a Finnish biotechnology company developing its proprietary IPSAT™ (“Intestinal Protection System in Antibiotic Treatment”) family of products for the prevention of hospita...

OS Therapies Inc.

OS Therapies Inc. (OST) is a clinical stage therapeutic company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS). OS Therapies was launched to meet...

EnClear Therapies

EnClear Therapies is a Cambridge (USA) based biotechnology company developing neurology-focused, device-based systems that remove toxic proteins as therapies for the treatment of ...

Toler RX Incorporated

TolerRx, Inc. is an emerging biopharmaceutical enterprise specializing in the discovery, development, and commercial launch of a novel class of therapies that induce and/or maintain immunological tole...

MolMed S.p.A.

Since year 2000, MolMed has evolved into a biotechnology drug-developing company, with a primary focus on novel cancer therapies. Today, MolMed is an integrated company covering all functions, from di...

More Information about "Ipsat Therapies Oy" on BioPortfolio

We have published hundreds of Ipsat Therapies Oy news stories on BioPortfolio along with dozens of Ipsat Therapies Oy Clinical Trials and PubMed Articles about Ipsat Therapies Oy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Ipsat Therapies Oy Companies in our database. You can also find out about relevant Ipsat Therapies Oy Drugs and Medications on this site too.

Quick Search

Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

MRSA (methicillin-resistant Staphylococcus aureus)
MRSA (methicillin-resistant Staphylococcus aureus) is a family of bacteria with resistance to one or more major antibiotics. There are currently 17 different strains of MRSA. Two particular strains, EMRSA15 and EMRSA16  account for 96% of MRSA blood...

Corporate Database Quicklinks

Searches Linking to this Company Record